Sign up USA
Proactive Investors - Run By Investors For Investors

Recce to reveal submission details from FDA

The halt will remain in place until Thursday 16th November 2017.
Recce to reveal submission details from FDA
The company's shares are in pre-open

Recce Ltd (ASX:RCE) has been granted a trading halt by the ASX pending the receipt of information from the United States Food and Drug Administration (FDA) following Recce’s recent data submission.

Recce is focused on the development of a new class of synthetic antibiotics.

The halt will remain in place until the opening of trade on Thursday 16th November 2017, or earlier if an announcement is made to the market.

View full RCE profile View Profile

Recce Ltd Timeline

Related Articles

lupus poster
January 18 2018
The last of the 200 patients has had their final assessment and the data is now being processed and analysed
Picture of growing facility
May 07 2018
Establishing a vertically integrated business model provides THC with the ability to optimise efficiencies in the manufacturing process.
spreadsheet and calculator
January 25 2018
According to one City number cruncher, Ergomed’s drugs safety unit alone is worth as much as the whole business
Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use